APO Research
Talk to an analyst

APO RESEARCH · REPORT

Musculoskeletal Disorder Stem Cell Therapy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Musculoskeletal Disorder Stem Cell Therapy Market Outlook and Growth Opportunities 2026

22 December 2025190 pages

Choose your research edition.

Industry ResearchMusculoskeletal Disorder Stem Cell Therapy Industry Research Report 2026102 pages · $2,950 USDIndustry Growth & TrendsGlobal Musculoskeletal Disorder Stem Cell Therapy Industry Growth and Trends Forecast to 203260 pages · $3,450 USDMarket StructureGlobal Musculoskeletal Disorder Stem Cell Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032176 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Musculoskeletal Disorder Stem Cell Therapy Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Musculoskeletal Disorder Stem Cell Therapy Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Musculoskeletal Disorder Stem Cell Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Musculoskeletal Disorder Stem Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Musculoskeletal Disorder Stem Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Musculoskeletal Disorder Stem Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Musculoskeletal Disorder Stem Cell Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Musculoskeletal Disorder Stem Cell Therapy market include Takeda (TiGenix), Osiris Therapeutics and NuVasive, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Musculoskeletal Disorder Stem Cell Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Musculoskeletal Disorder Stem Cell Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Musculoskeletal Disorder Stem Cell Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Musculoskeletal Disorder Stem Cell Therapy market.

Musculoskeletal Disorder Stem Cell Therapy Segment by Company

Takeda (TiGenix)

Osiris Therapeutics

NuVasive

Musculoskeletal Disorder Stem Cell Therapy Segment by Type

Allogeneic

Autologous

Musculoskeletal Disorder Stem Cell Therapy Segment by Application

Muscle disease

Skeletal disease

Musculoskeletal Disorder Stem Cell Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Musculoskeletal Disorder Stem Cell Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Musculoskeletal Disorder Stem Cell Therapy key companies, revenue, market share, and recent developments.

3. To split the Musculoskeletal Disorder Stem Cell Therapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Musculoskeletal Disorder Stem Cell Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Musculoskeletal Disorder Stem Cell Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze Musculoskeletal Disorder Stem Cell Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Musculoskeletal Disorder Stem Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Musculoskeletal Disorder Stem Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Musculoskeletal Disorder Stem Cell Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Musculoskeletal Disorder Stem Cell Therapy industry.

Chapter 3: Detailed analysis of Musculoskeletal Disorder Stem Cell Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Musculoskeletal Disorder Stem Cell Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Musculoskeletal Disorder Stem Cell Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Musculoskeletal Disorder Stem Cell Therapy Industry Trends Table 2. Musculoskeletal Disorder Stem Cell Therapy Industry Drivers Table 3. Musculoskeletal Disorder Stem Cell Therapy Industry Opportunities and Challenges Table 4. Musculoskeletal Disorder Stem Cell Therapy Industry Restraints Table 5. Global Musculoskeletal Disorder Stem Cell Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Musculoskeletal Disorder Stem Cell Therapy Revenue Share by Company (2021-2026) Table 7. Global Musculoskeletal Disorder Stem Cell Therapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Musculoskeletal Disorder Stem Cell Therapy Key Company Manufacturing Base & Headquarters Table 9. Global Musculoskeletal Disorder Stem Cell Therapy Company, Product Type & Application Table 10. Global Musculoskeletal Disorder Stem Cell Therapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Musculoskeletal Disorder Stem Cell Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Allogeneic Table 15. Significant Companies of Autologous Table 16. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type (2021-2026) Table 20. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Muscle disease Table 22. Significant Companies of Skeletal disease Table 23. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application (2021-2026) Table 27. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application (2027-2032) Table 28. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Region (2021-2026) Table 31. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Region (2027-2032) Table 33. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value Market Share by Country (2021-2026) Table 36. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value Market Share by Country (2027-2032) Table 38. Takeda (TiGenix) Company Information Table 39. Takeda (TiGenix) Business Overview Table 40. Takeda (TiGenix) Musculoskeletal Disorder Stem Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Takeda (TiGenix) Musculoskeletal Disorder Stem Cell Therapy Product Portfolio Table 42. Takeda (TiGenix) Recent Development Table 43. Osiris Therapeutics Company Information Table 44. Osiris Therapeutics Business Overview Table 45. Osiris Therapeutics Musculoskeletal Disorder Stem Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Osiris Therapeutics Musculoskeletal Disorder Stem Cell Therapy Product Portfolio Table 47. Osiris Therapeutics Recent Development Table 48. NuVasive Company Information Table 49. NuVasive Business Overview Table 50. NuVasive Musculoskeletal Disorder Stem Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. NuVasive Musculoskeletal Disorder Stem Cell Therapy Product Portfolio Table 52. NuVasive Recent Development Table 53. Research Programs/Design for This Report Table 54. Authors List of This Report Table 55. Secondary Sources Table 56. Primary Sources List of Figures Figure 1. Musculoskeletal Disorder Stem Cell Therapy Product Image Figure 2. Global Musculoskeletal Disorder Stem Cell Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Musculoskeletal Disorder Stem Cell Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global Musculoskeletal Disorder Stem Cell Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Allogeneic Image Figure 8. Autologous Image Figure 9. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type (2021-2032) Figure 12. Muscle disease Image Figure 13. Skeletal disease Image Figure 14. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application (2021-2032) Figure 17. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Musculoskeletal Disorder Stem Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 20. North America Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Musculoskeletal Disorder Stem Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Musculoskeletal Disorder Stem Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Musculoskeletal Disorder Stem Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 26. South America Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Musculoskeletal Disorder Stem Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Allogeneic
  • Autologous
Applications
  • Muscle disease
  • Skeletal disease
Companies covered
  • Takeda (TiGenix)
  • Osiris Therapeutics
  • NuVasive

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Musculoskeletal Disorder Stem Cell Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Musculoskeletal Disorder Stem Cell Therapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Musculoskeletal Disorder Stem Cell Therapy Market Dynamics
  1. 2.1 Musculoskeletal Disorder Stem Cell Therapy Industry Trends
  2. 2.2 Musculoskeletal Disorder Stem Cell Therapy Industry Drivers
  3. 2.3 Musculoskeletal Disorder Stem Cell Therapy Industry Opportunities and Challenges
  4. 2.4 Musculoskeletal Disorder Stem Cell Therapy Industry Restraints
3 Musculoskeletal Disorder Stem Cell Therapy Market by Company
  1. 3.1 Global Musculoskeletal Disorder Stem Cell Therapy Company Revenue Ranking in 2025
  2. 3.2 Global Musculoskeletal Disorder Stem Cell Therapy Revenue by Company (2021-2026)
  3. 3.3 Global Musculoskeletal Disorder Stem Cell Therapy Company Ranking (2024-2026)
  4. 3.4 Global Musculoskeletal Disorder Stem Cell Therapy Company Manufacturing Base and Headquarters
  5. 3.5 Global Musculoskeletal Disorder Stem Cell Therapy Company Product Type and Application
  6. 3.6 Global Musculoskeletal Disorder Stem Cell Therapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Musculoskeletal Disorder Stem Cell Therapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Musculoskeletal Disorder Stem Cell Therapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Musculoskeletal Disorder Stem Cell Therapy Market by Type
  1. 4.1 Musculoskeletal Disorder Stem Cell Therapy Type Introduction
  2. 4.1.1 Allogeneic
  3. 4.1.2 Autologous
  4. 4.2 Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Type
  5. 4.2.1 Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Type (2021-2032)
  7. 4.2.3 Global Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type (2021-2032)
5 Musculoskeletal Disorder Stem Cell Therapy Market by Application
  1. 5.1 Musculoskeletal Disorder Stem Cell Therapy Application Introduction
  2. 5.1.1 Muscle disease
  3. 5.1.2 Skeletal disease
  4. 5.2 Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Application
  5. 5.2.1 Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Application (2021-2032)
  7. 5.2.3 Global Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application (2021-2032)
6 Musculoskeletal Disorder Stem Cell Therapy Regional Value Analysis
  1. 6.1 Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Musculoskeletal Disorder Stem Cell Therapy Sales Value (2021-2032)
  7. 6.3.2 North America Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Musculoskeletal Disorder Stem Cell Therapy Sales Value (2021-2032)
  10. 6.4.2 Europe Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Musculoskeletal Disorder Stem Cell Therapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Musculoskeletal Disorder Stem Cell Therapy Sales Value (2021-2032)
  16. 6.6.2 South America Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Musculoskeletal Disorder Stem Cell Therapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Country, 2025 VS 2032
7 Musculoskeletal Disorder Stem Cell Therapy Country-level Value Analysis
  1. 7.1 Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global Musculoskeletal Disorder Stem Cell Therapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Musculoskeletal Disorder Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Musculoskeletal Disorder Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda (TiGenix)
  2. 8.1.1 Takeda (TiGenix) Company Information
  3. 8.1.2 Takeda (TiGenix) Business Overview
  4. 8.1.3 Takeda (TiGenix) Musculoskeletal Disorder Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda (TiGenix) Musculoskeletal Disorder Stem Cell Therapy Product Portfolio
  6. 8.1.5 Takeda (TiGenix) Recent Developments
  7. 8.2 Osiris Therapeutics
  8. 8.2.1 Osiris Therapeutics Company Information
  9. 8.2.2 Osiris Therapeutics Business Overview
  10. 8.2.3 Osiris Therapeutics Musculoskeletal Disorder Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Osiris Therapeutics Musculoskeletal Disorder Stem Cell Therapy Product Portfolio
  12. 8.2.5 Osiris Therapeutics Recent Developments
  13. 8.3 NuVasive
  14. 8.3.1 NuVasive Company Information
  15. 8.3.2 NuVasive Business Overview
  16. 8.3.3 NuVasive Musculoskeletal Disorder Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 NuVasive Musculoskeletal Disorder Stem Cell Therapy Product Portfolio
  18. 8.3.5 NuVasive Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst